Innovation for better health. Our commitment
is to bring to patients around the world quality
medicines for use in diag nosing, combating and
preventing disease. Every day we work against time,
researching new pathways, new molecules, new
technologies – complementing our own capabilities
with exper tise of innovative partners from science
and industry.
The success of this work is evidenced in new
medicinesforareaswithsignificantunmetmedical
need such as oncology, cardiovascular and blood
diseases, as well as gynecology and ophthalmology.
Our aim is a better quality of life for all.
You need commitment, focus and
passion to find new ways to fight the
diseases of this world: innovation
is at the heart of it.
www.bayerhealthcare.com
www.bayerpharma.com
29409006_BHC_Imageanzeige_210x297_mm_Lay_20130515_TR.indd 1
15.05.13 14:03
18
BioTOPics 46 | September 2013
BioTOP-Report
Diagnostics
An Excellent Location for the Development of
Innovative Diagnostics
In Berlin-Brandenburg bioanalysis is a focus area of research and development. Some 100 companies and
more than 20 research facilities present the entire value chain from biomarker identification through clinical
validation to the production of in vitro-diagnostics.
Early, specific and reliable laboratory diagnostics makes a key
contribution to disease detection, therapy optimisation, and pre-
vention. Its importance can therefore barely be overrated, given
the many challenges facing our healthcare systems. Progress in
biomedical basic research and the development of new analytical
techniques and methods has resulted in a tremendous increase
in the performance of diagnostic laboratories over the past de-
cades.
New sensor-actor molecules, autonomous biosensors, genome,
proteome and glycan-based multiplex analytics as well as metab-
olomics platforms provide the foundation for the development
and implementation of innovative biomarker strategies. Com-
panion diagnostics for personalised medicine are rapidly gaining
in importance based on these new insights and developments.
In light of this, Berlin-Brandenburg has become an internation-
ally leading location for research and development in laboratory
medicine and for the implementation of clinical studies. The wide
range of specialised hospitals, clinics for both basic and advanced
care as well as the high-performance university medicine at the
Charité provide access to patient cohorts of the urban and ru-
ral population with some 180 different ethnic backgrounds and
covering virtually all medical themes. The development of the
German capital region as an internationally desired location for
diagnostics development is an outstanding example for the suc-
cessful implementation of the Common Innovation Strategy of
the States of Berlin and Brandenburg (innoBB) and a major com-
ponent of the HealthCapital cluster.
Diagnostic know-how for outstanding development
and patient care
Labor Berlin – Charité Vivantes GmbH is Europe‘s largest clini-
cal laboratory, providing optimal conditions for driving the de-
velopment of innovative diagnostics in cooperation with leading
companies like BioMérieux, Roche Diagnostics and Thermo Fish-
er Scientific. Labor Berlin is participating in the development of
a fully integrated automation solution in microbiology and has
introduced a platform for next-generation sequencing (NGS) into
routine analysis.
Since April 2013, the clinical laboratory has been standardising
its operations in a single location at the Charité Campus Vir-
Dr. Florian Kainzinger
Managing Director
Labor Berlin – Charité Vivantes GmbH
With our new central location, we have established the foun-
dation for intensive interdisciplinary exchange between the
specialist laboratories and for the integration of clinical exper-
tise. This high expertise, methodological competence and our
high routine sample volumes of more than 35 million analyses
per annum for more than 400,000 hospital and some one
million outpatients contribute to optimal patient care, while
also forming an ideal basis for the development of improved
IVD technologies.
Ene
rgy
Aut
omation
Phot
onics
Indus
trial Sof
tware
Sof
twa
re
Inter
net & T
elecommunication
Media & E-commerce
Life Science
Mater
ial Science
Nanotechnology & Chemis
try
I N V E S T O R S O F H I G H - T E C H G R U E N D E R F O N D S I I
Achieve innovation,
shape the future
High Tech Gruenderfonds is your partner for Seed Stage investing. We
help out young, high potential startups in the early phases of technology
and product development, as well as successful launching. Our assistance
is not limited to our cash investments, instead we strive to add long term
added-value to portfolio companies through our extensive network of
professional and our accredited coaches.
High-Tech Gründerfonds Management GmbH
Schlegelstraße 2 | 53113 Bonn
Phone: +49 (0)228-823001-00 | Fax: +49 (0)228-823000-50
E-Mail: info@htgf.de
http: // www.high-tech-gruenderfonds.de
Start shot for young technology companies